RU2010126596A - ПРИМЕНЕНИЕ ШТАММА L. casei ДЛЯ ПОЛУЧЕНИЯ КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ АКТИВАЦИИ ТУЧНЫХ КЛЕТОК - Google Patents

ПРИМЕНЕНИЕ ШТАММА L. casei ДЛЯ ПОЛУЧЕНИЯ КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ АКТИВАЦИИ ТУЧНЫХ КЛЕТОК Download PDF

Info

Publication number
RU2010126596A
RU2010126596A RU2010126596/15A RU2010126596A RU2010126596A RU 2010126596 A RU2010126596 A RU 2010126596A RU 2010126596/15 A RU2010126596/15 A RU 2010126596/15A RU 2010126596 A RU2010126596 A RU 2010126596A RU 2010126596 A RU2010126596 A RU 2010126596A
Authority
RU
Russia
Prior art keywords
use according
composition
strain
specified
mast cells
Prior art date
Application number
RU2010126596/15A
Other languages
English (en)
Russian (ru)
Inventor
Сесиль ШИФФЕР-МАННИУИ (FR)
Сесиль ШИФФЕР-МАННИУИ
Марк ДАЕРОН (FR)
Марк ДАЕРОН
Сандрин САМСОН (FR)
Сандрин САМСОН
Рафаэлль БУРДЕ-СИКАР (FR)
Рафаэлль Бурде-Сикар
Original Assignee
Энститю Пастеэр (Fr)
Энститю Пастеэр
Компани Жервэ Данон (Fr)
Компани Жервэ Данон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Энститю Пастеэр (Fr), Энститю Пастеэр, Компани Жервэ Данон (Fr), Компани Жервэ Данон filed Critical Энститю Пастеэр (Fr)
Publication of RU2010126596A publication Critical patent/RU2010126596A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
RU2010126596/15A 2007-11-30 2008-12-01 ПРИМЕНЕНИЕ ШТАММА L. casei ДЛЯ ПОЛУЧЕНИЯ КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ АКТИВАЦИИ ТУЧНЫХ КЛЕТОК RU2010126596A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291431.0 2007-11-30
EP07291431A EP2065048A1 (en) 2007-11-30 2007-11-30 Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation

Publications (1)

Publication Number Publication Date
RU2010126596A true RU2010126596A (ru) 2012-01-10

Family

ID=39323735

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010126596/15A RU2010126596A (ru) 2007-11-30 2008-12-01 ПРИМЕНЕНИЕ ШТАММА L. casei ДЛЯ ПОЛУЧЕНИЯ КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ АКТИВАЦИИ ТУЧНЫХ КЛЕТОК

Country Status (7)

Country Link
US (1) US20100284973A1 (https=)
EP (2) EP2065048A1 (https=)
JP (1) JP2011505349A (https=)
CN (1) CN101909643A (https=)
AR (1) AR069520A1 (https=)
RU (1) RU2010126596A (https=)
WO (1) WO2009068997A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924307B1 (fr) * 2007-12-04 2010-08-27 Gervais Danone Sa Utilisation de l. casei ssp. paracasei comme antifongique
WO2010013143A2 (en) * 2008-08-01 2010-02-04 Institut Pasteur Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
US20130121976A1 (en) * 2010-03-12 2013-05-16 Agusti Montserrat Carreras Lactic Acid Bacteria for Coeliac Disease
KR101275227B1 (ko) * 2010-10-13 2013-06-18 광주과학기술원 중증근무력증 예방, 개선 또는 치료용 조성물
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN103257237B (zh) * 2013-05-09 2015-05-20 中国农业大学 一种食品中过敏原的体外检测方法
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
WO2016102950A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Immune modulation
HRP20191949T1 (hr) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
ME03511B (me) * 2015-06-15 2020-04-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN109312297B (zh) * 2015-12-11 2022-09-23 精密生物集团有限公司 用于治疗肥胖症和相关代谢病的干酪乳杆菌
SG10201913557TA (en) 2016-03-04 2020-02-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
ES2877726T3 (es) 2017-05-22 2021-11-17 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
TWI812624B (zh) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
ES2841902T3 (es) 2017-06-14 2021-07-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3738599B1 (en) * 2018-01-12 2023-12-27 GI Innovation, Inc. Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof
CN109266584B (zh) * 2018-10-18 2020-09-08 扬州大学 一株具有肥大细胞活性调节作用的纤毛型鼠李糖乳杆菌及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617758B2 (ja) * 1988-03-25 1997-06-04 株式会社ヤクルト本社 抗体産生増強型免疫賦活剤
CN1099271A (zh) * 1993-08-23 1995-03-01 王世荣 生态口服液
CN1114354A (zh) * 1994-06-23 1996-01-03 江苏省纺织(集团)总公司实业开发分公司 双歧杆菌在含中药培养基中进行有氧发酵的方法
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
PE20030283A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
CN1289092C (zh) * 2002-10-29 2006-12-13 西安大鹏生物科技股份有限公司 一种肠道微生态调节剂
FR2848115B1 (fr) * 2002-12-05 2005-03-25 Rhodia Chimie Sa Composition de bacteries et son utilisation
DK1675481T3 (da) * 2003-10-24 2009-01-19 Nutricia Nv Synbiotisk præparat til börn
CN100396771C (zh) * 2004-05-10 2008-06-25 景岳生物科技股份有限公司 新的微生物株类干酪乳杆菌gm-080及其治疗过敏相关疾病的用途
US7351572B2 (en) * 2004-10-15 2008-04-01 Genmont Biotech Inc. Microorganism strain GM-090 of Lactobacillus fermentum and its use for stimulating IFN-γ secretion and/or treating allergy
EP1683425A1 (en) * 2005-01-21 2006-07-26 Compagnie Gervais Danone Use of a fermented milk containing L. Casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction
WO2007035057A1 (en) * 2005-09-23 2007-03-29 Gwangju Institute Of Science And Technology Composition for preventing or treating artritis comprising lactic acid bacteria and collangen as active ingredients
CN100556414C (zh) * 2005-10-14 2009-11-04 德阳创新生物工程有限公司 一种具免疫调节功能的多菌组合物及其制备方法与用途
JP2007117031A (ja) * 2005-10-31 2007-05-17 Nakagaki Gijutsushi Jimusho:Kk インターフェロンガンマ発現誘導作用を有する発酵乳、及び発酵乳製造用種菌

Also Published As

Publication number Publication date
US20100284973A1 (en) 2010-11-11
WO2009068997A1 (en) 2009-06-04
EP2065048A1 (en) 2009-06-03
CN101909643A (zh) 2010-12-08
AR069520A1 (es) 2010-01-27
JP2011505349A (ja) 2011-02-24
EP2224936A1 (en) 2010-09-08

Similar Documents

Publication Publication Date Title
RU2010126596A (ru) ПРИМЕНЕНИЕ ШТАММА L. casei ДЛЯ ПОЛУЧЕНИЯ КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ АКТИВАЦИИ ТУЧНЫХ КЛЕТОК
Imaoka et al. Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells
Esteban‐Fernández et al. In vitro beneficial effects of Streptococcus dentisani as potential oral probiotic for periodontal diseases
AU2018333114B2 (en) New use for treatment of Clostridium difficile infections
Amara et al. Role of Probiotics in health improvement, infection control and disease treatment and management
JP2011505349A5 (https=)
Upadrasta et al. Probiotics and blood pressure: current insights
Salazar et al. Production of exopolysaccharides by Lactobacillus and Bifidobacterium strains of human origin, and metabolic activity of the producing bacteria in milk
Basannavar et al. Effect of Aloe vera (Aloe barbadensis Miller) on survivability, extent of proteolysis and ACE inhibition of potential probiotic cultures in fermented milk
US9011839B2 (en) Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing Lactobacillus
Gong et al. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials
Şanlidere Aloğlu et al. Assimilation of cholesterol and probiotic characterisation of yeast strains isolated from raw milk and fermented foods
Kitazawa et al. Probiotics: immunobiotics and immunogenics
RU2010117248A (ru) ПРИМЕНЕНИЕ ШТАММА Вifidobacterium ДЛЯ ПОЛУЧЕНИЯ КОМПОЗИЦИИ, ПРЕДНАЗНАЧЕННОЙ ДЛЯ ПРОФИЛАКТИКИ И/ИЛИ ЛЕЧЕНИЯ ПРОЯВЛЕНИЙ АЛЛЕРГИЧЕСКОГО ТИПА
Liu et al. Evidence from comparative genomic analyses indicating that Lactobacillus-mediated irritable bowel syndrome alleviation is mediated by conjugated linoleic acid synthesis
Snel et al. Strain‐specific immunomodulatory effects of Lactobacillus plantarum strains on birch‐pollen‐allergic subjects out of season
CN119351286B (zh) 一种具有免疫调节功能的短双歧杆菌BBr69及其应用、产品和方法
RU2011124924A (ru) Штамм lactobacillus delbrueckii, снижающий содержание холестерина в крови
Sánchez et al. Technological and probiotic selection criteria of a bile-adapted Bifidobacterium animalis subsp. lactis strain
Xie et al. Lacticaseibacillus rhamnosus KY16 improves depression by promoting intestinal secretion of 5-HTP and altering the gut microbiota
Tang et al. Screening of lactic acid bacteria isolated from fermented Cornus officinalis fruits for probiotic potential
KR102369996B1 (ko) 대사성 질환과 안질환의 예방 및 건강 유지를 위한 장내 미생물 검사 기반 맞춤형 프리바이오틱스 또는 프로바이오틱스 정보 제공방법
CN105420150A (zh) 一种嗜酸乳杆菌及其应用
Jung et al. Effects of Lactobacillus curvatus MG5246 on inflammatory markers in Porphyromonas gingivalis lipopolysaccharide-sensitized human gingival fibroblasts and periodontitis rat model
Hati et al. Safety aspects, probiotic potentials of yeast and Lactobacillus isolated from fermented foods in North-Eastern India, and its anti-inflammatory activity